Shares of Enzo Biochem Inc. (NYSE:ENZ) fell 4.4% during trading on Friday . The stock traded as low as $6.36 and last traded at $6.37, with a volume of 180,364 shares changing hands. The stock had previously closed at $6.66.

Separately, Zacks Investment Research lowered Enzo Biochem from a “buy” rating to a “hold” rating in a report on Tuesday, August 9th.

The stock has a market cap of $294.24 million and a price-to-earnings ratio of 16.65. The firm’s 50-day moving average is $6.38 and its 200-day moving average is $5.37.

Enzo Biochem (NYSE:ENZ) last issued its quarterly earnings results on Wednesday, June 8th. The company reported ($0.04) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.06) by $0.02. The business had revenue of $18.16 million for the quarter, compared to analysts’ expectations of $24.50 million. During the same period in the prior year, the company earned ($0.07) EPS. Analysts expect that Enzo Biochem Inc. will post ($0.23) EPS for the current year.

Enzo Biochem, Inc (Enzo) is an integrated life science and biotechnology company, which is engaged in the research, development, manufacturing and marketing of diagnostic and research products based on genetic engineering, biotechnology and molecular biology. These products are designed for the diagnosis of and/or screening for infectious diseases, cancers, genetic defects and other medically pertinent diagnostic information and are distributed in the United States and internationally.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.